Navigation Links
Next Safety, Inc.'s Innovative Drug Delivery System Will Replace,Cigarettes and Significantly Advance Pulmonary Medication Delivery

WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety, Inc. has identified basic scientific mechanisms that promise to revolutionize pulmonary drug delivery. This proprietary technology uses a stream of purified air to deliver medications deep into the pulmonary system. It is considered superior to other drug delivery systems because it rapidly administers aerosolized drugs to the lining of the lungs at previously unrealized efficiencies. The delivery technique has multiple applications across many therapeutic areas, such as asthma and nicotine replacement. Preliminary findings indicate that the Next Safety device delivers nicotine more efficiently than cigarettes, but without the negative effects of smoke.

According to estimates by the World Health Organizations smoking kills 5 million people globally each year. In 20 years, smoking will kill more than 10 million people per year. Half of the 1.3 billion smokers in the world today (650 million) will die from their habit.

"Our technology will save more lives than have been lost in all the wars in recorded history" - C. Eric Hunter, CEO and Founder of Next Safety, Inc.

"The fundamental nature of this development means that pulmonary delivery for a wide range of drug classes will be vastly improved or enabled," said Tom Stern, MD, assistant professor of medicine in the Department of Internal Medicine at Carolinas Medical Center and member of Next Safety's Medical Advisory Board. "To date laboratory data suggests applications such as childhood asthma or home delivery of medicines previously requiring an IV will be equally benefited. Although further testing is needed, this fundamental breakthrough may eventually be seen as important as the invention of the syringe."

"We've taken a fresh approach to pulmonary drug delivery," said Lyndell Duvall, director of technology & product development for Next Safety, Inc. "By obeying mother nature, and borrowing techniques and materials from the semiconductor industry, we are able to individually generate each droplet in an aerosol and dictate how it will behave before it is delivered to the patient."

The company is planning clinical testing under an IRB protocol that will include antibiotics, phenergan, albuterol, tobramycin, and morphine. The tests will be conducted in coordination with Carolinas Medical Center, located in Charlotte, NC. Early results should be available July 07'.

Next Safety is located in North Carolina, an area already known for leadership in technology and medicine. The company has leveraged this expertise to develop the worlds most advanced respirator technology and to advance the field of pulmonary medicine. Next Safety's bPure8000(TM) line of respirators provide higher protection against airborne viruses and fine particulate air pollution than any other respirator available globally. Next Safety now brings the same innovative approach to the science of pulmonary drug delivery and nicotine replacement.

For more information about Next Safety, Inc. visit www.nextsafety.com.

Contact

Next Safety, Inc.
Bethany Swaim, 336-246-7700


'"/>




Related medicine technology :

1. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
2. Bionovos MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
3. Oncolytics Biotech Inc.s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference
4. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
5. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
6. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
7. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
8. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
9. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
10. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Direct-to-consumer digital marketing ... and 65% increase in consumable sales, quarter-over-quarter ... DRIO ), a leader in digital health ... Dario™ Blood Glucose Monitoring System, an all-in-one diabetes meter, ... and minimally invasive smart diabetes management solution. ...
(Date:1/23/2017)... plc, (NYSE: AGN ), a leading global pharmaceutical ... Academy (IHA). Designed to inspire a long-term commitment to Headache ... three-day, intensive overview on research and treatment options. This is ... since the inception of IHA in North America ... in 2014. "Allergan is dedicated ...
(Date:1/23/2017)... 2017  Using Astute Medical,s NephroCheck Test ... acute kidney injury (AKI) after open-heart surgery and ... guidelines significantly improved outcomes by reducing the ... 33 percent, according to a study ... Care Medicine. Experience the interactive ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... During the ... Carol Francis, Psychologist in the South Bay area , explained “Watching Women’s ... all people and by all people shines as a bright beacon of determination ...
(Date:1/24/2017)... ... , ... The National Council of Alcoholism and Drug Dependence ( NCADD ), ... communities to designate the last full week of January as National Drug and Alcohol ... Myths.” As a community, we can advocate for effective treatment, but also especially ...
(Date:1/23/2017)... New York, NY (PRWEB) , ... January 23, 2017 , ... ... firm, announced today that John J. Nelson, a senior accountant at the Firm, will ... behalf of Make-A-Wish® Hudson Valley. Over 200 runners will race up 1,576 steps, a ...
(Date:1/23/2017)... , ... January 23, 2017 , ... ... educational institution’s inaugural K-20 Education Summit to be held March 23-25, 2017 in ... by Jan. 25, 2017. , The keynote speakers include Dr. Michelle R. Weise, ...
(Date:1/23/2017)... ... 23, 2017 , ... The iaedp Foundation, recognized for its ... who treat the full spectrum of eating disorder problems, proudly announces the addition ... of the leading eating disorder treatments centers located throughout the U.S. As partners ...
Breaking Medicine News(10 mins):